Gritstone Oncology

General Information


We are an immuno-oncology company developing tumor-specific cancer immunotherapies to fight multiple cancer types. Our approach harnesses the natural power of a patient’s own immune system to recognize short tumor-specific peptide sequences presented on cancer cells, referred to as tumor-specific neoantigens, or TSNA, in order to destroy tumor cells. We expect to initiate a Phase 1/2 clinical trial of our first personalized immunotherapy product candidate, GRANITE-001, in the second half of 2018 for the treatment of multiple common solid tumors.

Employees: 100
Founded: 2015
Contact Information
Address 5858 Horton Street, Suite 210, Emeryville, CA 94608, US
Phone Number (510) 871-6100.
Web Address
View Prospectus: Gritstone Oncology
Financial Information
Market Cap $432.4mil
Revenues $0 mil (last 12 months)
Net Income $-55.8 mil (last 12 months)
IPO Profile
Symbol GRTS
Exchange NASDAQ
Shares (millions): 6.7
Price range $15.00 - $15.00
Est. $ Volume $100.0 mil
Manager / Joint Managers Goldman Sachs/ Cowen/ Barclays
CO-Managers BTIG
Expected To Trade: 9/28/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change